Financial reports
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
31 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
24 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
Current reports
8-K
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
9 Apr 24
8-K
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory
21 Mar 24
8-K
Unregistered Sales of Equity Securities
8 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Dec 23
8-K
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq’s Bid Price Rule
8 Nov 23
8-K
Entry into a Material Definitive Agreement
5 Oct 23
8-K
Jaguar Health Reports Second Quarter 2023 Financial Results
14 Aug 23
8-K
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
7 Jul 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
D
$60.00 k in equity / Common Stock, sold $60.00 k, 1 investor
30 Nov 23
S-8
Registration of securities for employees
14 Aug 23
S-8
Registration of securities for employees
15 May 23
D
$1.83 mm in equity / options, sold $1.83 mm, 3 investors
11 May 23
D
$1.86 mm in equity / options, sold $1.86 mm, 6 investors
11 May 23
S-8
Registration of securities for employees
6 Apr 23
D
$7.14K in equity, sold $7.14K, 1 investor
23 Sep 22
D
$12M in debt / Royalty interest, sold $12M, 1 investor
2 Sep 22
Proxies
DEF 14A
Definitive proxy
15 Mar 24
PRE 14A
Preliminary proxy
5 Mar 24
DEF 14A
Definitive proxy
31 May 23
PRE 14A
Preliminary proxy
16 May 23
DEFR14A
Revised proxy
15 Dec 22
DEF 14A
Definitive proxy
28 Nov 22
PRE 14A
Preliminary proxy
18 Nov 22
DEF 14A
Definitive proxy
29 Aug 22
PRE 14A
Preliminary proxy
19 Aug 22
DEFA14A
Additional proxy soliciting materials
23 May 22
Other
EFFECT
Notice of effectiveness
6 Dec 21
CORRESP
Correspondence with SEC
1 Dec 21
UPLOAD
Letter from SEC
30 Nov 21
EFFECT
Notice of effectiveness
10 Jun 21
CORRESP
Correspondence with SEC
7 Jun 21
UPLOAD
Letter from SEC
4 Jun 21
EFFECT
Notice of effectiveness
24 Sep 20
CORRESP
Correspondence with SEC
21 Sep 20
UPLOAD
Letter from SEC
18 Sep 20
EFFECT
Notice of effectiveness
26 Jun 20
Ownership
4
Pravin R Chaturvedi
17 Apr 24
4
Jonathan S. Wolin
17 Apr 24
4
Carol R. Lizak
17 Apr 24
4
Steven R. King
17 Apr 24
4
LISA A CONTE
17 Apr 24
SC 13G
Iliad Research & Trading, L.P.
29 Dec 23
4
Anula Jayasuriya
14 Aug 23
4
Jonathan B. Siegel
14 Aug 23
4
JOHN MICEK
14 Aug 23
4
JAMES J BOCHNOWSKI
14 Aug 23